Digitisation | November 11, 2025
Nitinotes secures CE mark for automated suturing platform ‘EndoZip’
Enabling a new era in minimally invasive obesity treatment across Europe
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
